2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD19

CD19

CD19 is a 95 kD transmembrane glycoprotein that is highly expressed in human B cells and certain types of tumors, belonging to the immunoglobulin superfamily. CD19 plays a crucial role in regulating the threshold of B cell signaling by modulating both B cell receptor (BCR)-dependent and independent signaling pathways, thereby playing an essential role in the initiation of immune responses and the maintenance of tolerance. CD19 typically forms a multimolecular complex with molecules like CD21 and CD81 on the surface of mature B cells, where it exerts its dominant signaling function.
CD19 works in cooperation with the BCR to promote the activation of Src family protein tyrosine kinases, enhancing B cell proliferation and expansion. It can also independently enhance B cell activation by binding to the complement receptor CD21. Mice and humans lacking CD19 show weakened T cell-dependent immune responses and low levels of immunoglobulins, leading to immune dysfunction. High expression of CD19 is closely associated with B cell lymphoma, acute lymphoblastic leukemia (ALL), and other malignancies. CD19 monoclonal antibodies are used in the study of B cell malignancies[1].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991900
    LY3541860
    		Inhibitor ≥99.0%
    LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (Kd values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC50 = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases.
    LY3541860
  • HY-P990349
    Anti-CD19 Antibody
    		Inhibitor 99.91%
    The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD19 Antibody
  • HY-153085
    CD19 CAR circRNA
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR circRNA
  • HY-P99577
    Taplitumomab
    Taplitumomab is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
    Taplitumomab
  • HY-P991231
    DI-B4
    		Inhibitor
    DI-B4 is an anti-CD19 monoclonal antibody that can bind to CD19 on the surface of B cells and has anti-tumor activity.
    DI-B4
  • HY-P991542
    GBR-401
    		Inhibitor
    GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models.
    GBR-401
  • HY-P991839
    Anti-CD19 Antibody (FMC63)
    		Inhibitor
    Anti-CD19 Antibody (FMC63) is an anti-human CD19 antibody. Anti-CD19 Antibody (FMC63)recognizes an epitope in CD19 that is located between exons 2 and 4. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD19 Antibody (FMC63)
Cat. No. Product Name / Synonyms Application Reactivity